All Press Releases
Pila Pharma publishes interim report April 1 – June 30, 2022
Malmö, August 26, 2022 Download the press release as PDF here PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s interim report for the period April – June 2022. The report can be found on the Company´s website:https://pilapharma.com/investors/finansiell-information SUMMARY OF YEAR-END REPORT Second quarter (April 1 – June 30, 2022) Revenue was SEK 651 kSEK (0)Operating loss (EBIT) was…
Pila Pharma AB erhåller särläkemedelsstatus i USA
Malmö 15 juli 2022 Läs pressmeddelandet som PDF här Pila Pharma AB (publ) meddelar att US Food and Drug Administration, FDA, har beviljat Orphan Drug Designation (särläkemedelsstatus) för utvecklingskandidaten XEN-D0501 som behandling av erytromelalgi, en sällsynt sjukdom som orsakar episoder av brännande smärta och rodnad på grund av neurogen inflammation. Pila Pharmas kandidatmolekyl XEN-D0501 utvecklas annars för behandling av typ…
Pila Pharma AB is granted Orphan Drug Designation status in the USA
Malmö 15 July 2022 Download the press release as PDF here Pila Pharma AB (publ) announces that the US Food and Drug Administration, FDA, has granted Orphan Drug Designation (ODD) of the development candidate XEN-D0501 for treatment of erythromelalgia, a rare disease that causes episodes of burning pain and redness due to neurogenic inflammation. Pila Pharma's candidate molecule XEN-D0501 is…